ATAC IRON REAGENT, ATAC TIBC COLUMN KIT AND IRON CALIBRATOR (500 UG/DL)
K030528 · Clinical Data · JIY · Jun 17, 2003 · Clinical Chemistry
Device Facts
Record ID
K030528
Device Name
ATAC IRON REAGENT, ATAC TIBC COLUMN KIT AND IRON CALIBRATOR (500 UG/DL)
Applicant
Clinical Data
Product Code
JIY · Clinical Chemistry
Decision Date
Jun 17, 2003
Decision
SESE
Submission Type
Traditional
Regulation
21 CFR 862.1410
Device Class
Class 1
Intended Use
The ATAC Iron Reagent Kit, which contains both reagent and calibrator, is intended for use with the ATAC 8000 Random Access Chemistry System as a system for the quantitative determination of total iron in serum. The ATAC TIBC Column Kit, which is marketed with generic labeling and an ATAC 8000 Application Sheet, is intended for use with the ATAC Iron Reagent Kit and other iron reagents for the quantitative determination of total iron binding capacity in serum. Total iron results are used for the diagnosis and treatment of diciency anemia, hemochromatosis (a disease associated with widespread deposit in the tissues of two iron-containing pigments, and characterized by pigmentation of the skin), and chronic renal disease. Total iron binding capacity measurements are used for the diagnosis and treatment of anemia. This reagent is intended to be used by trained personnel in a professional setting and is not intended for home use.
Device Story
ATAC Iron Reagent Kit and TIBC Column Kit; used with ATAC 8000 Random Access Chemistry System. Iron Reagent strips iron from transferrin in low pH buffer; oxidizes to ferric ions; binds with Ferrozine. Absorbance measured at 546 nm; proportional to iron concentration. TIBC Column Kit pretreats serum; saturating reagent fills iron binding sites; alumina column removes unbound iron; filtrate assayed for iron. Used in clinical laboratory settings by trained personnel. Output provides quantitative iron/TIBC values; assists physicians in diagnosing/treating anemia, hemochromatosis, and chronic renal disease.
Clinical Evidence
Bench testing only. Linearity established for iron (25-500 µg/dL) and TIBC (125-500 µg/dL). Precision studies (n=60 per sample) showed within-run CVs of 1.1-2.2% and total CVs of 2.0-4.3%. Method comparison via Deming regression against competitive reagents (n=58 for iron, n=55 for TIBC) demonstrated strong correlation. Stability validated for 14 days onboard and 7 days calibration.
Technological Characteristics
In vitro diagnostic reagent kit; includes Ferrozine-based iron reagent and alumina-based TIBC column. Photometric sensing principle (546 nm absorbance). Designed for use on ATAC 8000 Random Access Chemistry System. Standalone reagent system; professional use only.
Indications for Use
Indicated for adult patients requiring quantitative determination of total serum iron and total iron binding capacity (TIBC) for the diagnosis and treatment of iron deficiency anemia, hemochromatosis, and chronic renal disease. For professional use only.
Regulatory Classification
Identification
An iron (non-heme) test system is a device intended to measure iron (non-heme) in serum and plasma. Iron (non-heme) measurements are used in the diagnosis and treatment of diseases such as iron deficiency anemia, hemochromatosis (a disease associated with widespread deposit in the tissues of two iron-containing pigments, hemosiderin and hemofuscin, and characterized by pigmentation of the skin), and chronic renal disease.
Predicate Devices
Beckman Synchron Systems Iron Reagent (product 467910)
Beckman Systems Fe/IBCT Calibrator (product 442772)
Beckman Synchron Systems Total Iron Binding Capacity (IBCT) Column Kit (product 465976)
Related Devices
K972363 — IL TEST IRON · Instrumentation Laboratory CO · Aug 15, 1997
K981279 — TIBC · Abbott Laboratories · May 20, 1998
K970248 — CANTROL SERUM IRON AND TOTAL IRON BINDING CAPACITY TEST SYSTEM · Canyon Diagnostics, Inc. · Feb 11, 1997
K061464 — VITROS CHEMISTRY PRODUCTS TIBC KIT, MODEL 886 7541; CALIBRATOR KIT 4, MODEL 120 4668 · Ortho-Clinical Diagnostics, Inc. · Jun 15, 2006
Submission Summary (Full Text)
{0}------------------------------------------------
## Clinical Data
JUN 1 7 2003
1075 W. Lambert Road Suite D Brea, CA 92821 T (714) 672-3553 F (714) 672-3554
K030528
## SUMMARY OF 510(K) SAFETY AND EFFECTIVENESS INFORMATION
This summary of 510(k) safety and effectiveness information is being submitted in accordance with the requirements of SMDA 1990 and 21 CFR 807.92.
The ATAC Iron Reagent Kit and ATAC TIBC Column Kit are intended for the quantitative determination of total iron and total iron binding capacity in serum. Total iron results are used for the diagnosis and treatment of diseases such as iron deficiency anemia, hemochromatosis (a disease associated with widespread deposit in the tissues of two iron-containing pigments, hemosiderin and hemofuscin, and characterized by pigmentation of the skin), and chronic renal iron binding capacity measurements are used for the diagnosis and treatment of anemia.
The ATAC Iron Reagent measures total serum iron by stripping it from the transferrin in a low pH reagent buffer, oxidizing it to ferric ions and binding it with Ferrozine. The resulting increase in absorbance at 546 nm is proportional to the iron concentration in the sample. The ATAC TIBC Column Kit is used to pretreat serum specimens prior analysis. The iron in the saturating reagent ensures that all available iron binding sites in the serum specimen are saturated with iron. The filtrate is assayed with an iron reagent after removing the unbound iron form the sample mixture by passing it through an alumina column. The maximum amount of iron bound in the specimen is a measure of its transferrin concentration.
The ATAC Iron Reagent Kit, which contains the Iron Calibrator (500 ug/dL), is substantially equivalent to the Beckman Synchron Systems Iron Reagent, product 467910 and the Beckman Systems Fe/IBCT Calibrator, product 442772. The ATAC TIBC Column Kit and ATAC 8000 TIBC application is substantially equivalent to the Beckman Synchron Systems Total Iron Binding Capacity (IBCT) Column Kit, product no. 465976 (Beckman Coulter, Inc. of Brea, CA).
The effectiveness of ATAC Total Iron Reagent Kit on the ATAC 8000 Random Access Chemistry System is shown in the following studies.
The recovery of iron using the ATAC Total Iron Reagent is linear from 25 to 500 µg/dL, as shown by the recovery of linearity standards that span the usable range. Regression statistics that compare standard values yield a standard error estimate of 3.1 ug/dL.
Precision is demonstrated by the replicate assay of commercially available control serum. Precision statistics, calculated analogous to the method described in NCCLS Guideline EP3-T, are shown below.
| Sample | n | mean | Within Run | | Total | |
|---------|----|------|------------|------|-------|------|
| | | | 1SD | %CV | 1SD | %CV |
| Serum 1 | 60 | 67 | 1.5 | 2.2% | 2.9 | 4.3% |
| Serum 2 | 60 | 177 | 1.9 | 1.1% | 4.4 | 2.5% |
| Serum 3 | 60 | 282 | 4.3 | 1.5% | 8.5 | 3.0% |
Serum specimens, collected from adult patients, were assayed for iron using the ATAC 8000 Random Access Chemistry System and another commercially available method. Results were compared by Deming regression and the following statistics were obtained.
> ATAC 8000 = 8.8 ug/dL + 0.969 x Competitive Reagent Sy.x = 3.0 µg/dL n = 58 range = 31 - 165 ug/dL
The 14 day onboard reagent stability and 7 day calibration stability claims are documented through the assay of serum controls over the claimed periods. In all cases, estimates of the total imprecision of iron recoveries over the test periods are less than the greater of 4 ug/dL or 4%.
{1}------------------------------------------------
The effectiveness of ATAC TIBC Column Kit is shown in the following studies with the ATAC Total Iron Reagent Kit on the ATAC 8000 Random Access Chemistry System.
TIBC recoveries using the ATAC TIBC Column Kit are linear from 125 to 500 µg/dL, as shown by the recovery of diluted serum pools that span the usable range. Regression statistics that compare standard recoveries to dilution factors yield an estimate of standard error of regression of 6 µg/dL.
Precision is demonstrated by the replicate assay of commercially available control serum. Precision statistics, calculated analogous to the method described in NCCLS Guideline EP3-T, are shown below.
| Sample | n | mean | Within Run | | Total | |
|---------|----|------|------------|------|-------|------|
| | | | 1SD | %CV | 1SD | %CV |
| Serum 1 | 60 | 247 | 4.5 | 1.8% | 4.9 | 2.0% |
| Serum 2 | 60 | 391 | 7.6 | 1.9% | 10.7 | 2.8% |
Serum specimens, collected from adult patients, were assayed for iron using the ATAC 8000 TIBC Application and another commercially available method. Results were compared by Deming regression and the following statistics were obtained.
> ATAC 8000 = 8.2 ug/dL + 0.964 x Competitive Reagent range = 237 - 470 ug/dL Sy.x = 7.8 µg/dL n = 55
Wynne Storkey
Wynn Stocking Manager of Regulatory Affairs Elan, Brea California
{2}------------------------------------------------
Image /page/2/Picture/1 description: The image shows the seal of the Department of Health & Human Services USA. The seal is circular and contains the words "DEPARTMENT OF HEALTH & HUMAN SERVICES USA" around the perimeter. In the center of the seal is a stylized image of a caduceus, which is a symbol of medicine. The caduceus has a staff with two snakes winding around it, and a pair of wings at the top.
Food and Drug Administration 2098 Gaither Road Rockville MD 20850
JUN 1 7 2003
Mr. Wynn Stocking Manager, Regulatory Affairs Clinical Data 1075 W. Lambert Road - Suite D Brea, CA 92821
Re: k030528
Trade/Device Name: ATAC Iron Reagent, Iron Calibrator and TIBC Column Kit Regulation Number: 21 CFR 862.1410 Regulation Name: Iron (non-heme) test system Regulatory Class: Class I Product Code: JIY; JMO Dated: June 3, 2003 Received: June 4, 2003
Dear Mr. Stocking:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); and good manufacturing practice requirements as set forth in the quality systems (OS) regulation (21 CFR Part 820).
{3}------------------------------------------------
Page 2 -
This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific information about the application of labeling requirements to your device, or questions on the promotion and advertising of your device, please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (301) 594-3084. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/dsma/dsmamain.html.
Sincercly yours,
Steven Putman
Steven I. Gutman, M.D., M.B.A. Director Office of In Vitro Diagnostic Device Evaluation and Safety Center for Devices and Radiological Health
Enclosure
{4}------------------------------------------------
510(k) Number (if known):
Image /page/4/Picture/1 description: The image shows a handwritten alphanumeric string. The string is "KO30528". The characters are written in a bold, slightly slanted style. The baseline of the text is underlined with a thick, dark line.
Device Name:
ATAC Iron Reagent, Iron Calibrator and TIBC Column Kit
Indications for Use:
The ATAC Iron Reagent Kit, which contains both reagent and calibrator, is intended for use with the ATAC 8000 Random Access Chemistry System as a system for the quantitative determination of total iron in serum. The ATAC TIBC Column Kit, which is marketed with generic labeling and an ATAC 8000 Application Sheet, is intended for use with the ATAC Iron Reagent Kit and other iron reagents for the quantitative determination of total iron binding capacity in serum.
Total iron results are used for the diagnosis and treatment of diciency anemia, hemochromatosis (a disease associated with widespread deposit in the tissues of two iron-containing pigments, and characterized by pigmentation of the skin), and chronic renal disease. Total iron binding capacity measurements are used for the diagnosis and treatment of anemia.
This reagent is intended to be used by trained personnel in a professional setting and is not intended for home use.
Jean Cooper
Division Sign-Off
Office of In Vitro Diagnostic Device Evaluation and Safety
510(k) K030528
(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of Device Evaluation (ODE)
Image /page/4/Picture/13 description: The image shows the phrase "Prescription Use" followed by "(Per 21 CFR 801.109)". There is a symbol to the right of the text. The symbol looks like an X.
OR
Over-The-Counter Use _________________________________________________________________________________________________________________________________________________________
(Optional Format 1-2-96)
Panel 1
/
Sort by
Ready
Predicate graph will load when search results are available.
Embedding visualization will load when search results are available.
PDF viewer will load when search results are available.
Loading panels...
Select an item from Submissions
Click any panel, subpart, regulation, product code, or device to see details here.
Section Matches
Results will appear here.
Product Code Matches
Results will appear here.
Special Control Matches
Results will appear here.
Loading collections...
Loading
My Alerts
You will receive email notifications based on the filters and frequency you set for each alert.
Sort by:
Create Alert
Search Filters
Agent Token
Create a read-only bearer token for Claude, ChatGPT, or other agents that can call HTTP APIs.